MiR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 58, Issue 1, 2013, Pages 119-125

  Castro, Rui E ^a   Ferreira, Duarte M S ^a   Afonso, Marta B ^a   Borralho, Pedro M ^a   MacHado, Mariana V ^b,c   Cortez Pinto, Helena ^b,c   Rodrigues, Cecília M P ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Apoptosis; miRNAs; NAFLD; p53; SIRT1; UDCA

Indexed keywords

BILE ACID; FATTY ACID; MICRORNA 34A; PLASMID VECTOR; PROTEIN P53; SIRTUIN 1; URSODEOXYCHOLIC ACID;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BARIATRIC SURGERY; CONTROLLED STUDY; DIETARY INTAKE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; LIVER BIOPSY; LIVER CELL; MALE; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; REPORTER GENE;

ANIMALS; APOPTOSIS; BIOPSY; FATTY LIVER; HEPATOCYTES; HUMANS; LIVER; MALE; MICRORNAS; OBESITY, MORBID; PRIMARY CELL CULTURE; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SIRTUIN 1; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; URSODEOXYCHOLIC ACID;

EID: 84871221881     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.08.008     Document Type: Article

References (38)

1. O. Cheung, and A.J. Sanyal Recent advances in nonalcoholic fatty liver disease Curr Opin Gastroenterol 25 2009 230 237
2. A. Canbay, S. Friedman, and G.J. Gores Apoptosis: the nexus of liver injury and fibrosis Hepatology 39 2004 273 278
3. D.M. Ferreira, R.E. Castro, M.V. Machado, T. Evangelista, A. Silvestre, and A. Costa Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease Diabetologia 54 2011 1788 1798
4. D. Sayed, and M. Abdellatif MicroRNAs in development and disease Physiol Rev 91 2011 827 887
5. O. Cheung, P. Puri, C. Eicken, M.J. Contos, F. Mirshahi, and J.W. Maher Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression Hepatology 48 2008 1810 1820
6. S. Li, X. Chen, H. Zhang, X. Liang, Y. Xiang, and C. Yu Differential expression of microRNAs in mouse liver under aberrant energy metabolic status J Lipid Res 50 2009 1756 1765
7. I.P. Pogribny, A. Starlard-Davenport, V.P. Tryndyak, T. Han, S.A. Ross, and I. Rusyn Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice Lab Invest 90 2010 1437 1446
8. H. Hermeking The miR-34 family in cancer and apoptosis Cell Death Differ 17 2010 193 199
9. M. Yamakuchi, M. Ferlito, and C.J. Lowenstein MiR-34a repression of SIRT1 regulates apoptosis Proc Natl Acad Sci USA 105 2008 13421 13426
10. T.C. Chang, E.A. Wentzel, O.A. Kent, K. Ramachandran, M. Mullendore, and K.H. Lee Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis Mol Cell 26 2007 745 752
11. A. Panasiuk, J. Dzieciol, B. Panasiuk, and D. Prokopowicz Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease World J Gastroenterol 12 2006 6198 6202
12. G.C. Farrell, C.Z. Larter, J.Y. Hou, R.H. Zhang, M.M. Yeh, and J. Williams Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression J Gastroenterol Hepatol 24 2009 443 452
13. C.M. Rodrigues, G. Fan, X. Ma, B.T. Kren, and C.J. Steer A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation J Clin Invest 101 1998 2790 2799
14. J.D. Amaral, R.E. Castro, S. Sola, C.J. Steer, and C.M. Rodrigues P53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis J Biol Chem 282 2007 34250 34259
15. R.E. Castro, S. Sola, X. Ma, R.M. Ramalho, B.T. Kren, and C.J. Steer A distinct microarray gene expression profile in primary rat hepatocytes incubated with ursodeoxycholic acid J Hepatol 42 2005 897 906
16. S. Sola, X. Ma, R.E. Castro, B.T. Kren, C.J. Steer, and C.M. Rodrigues Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta1-induced apoptosis of rat hepatocytes J Biol Chem 278 2003 48831 48838
17. R.E. Castro, D.M. Ferreira, X. Zhang, P.M. Borralho, A.L. Sarver, and Y. Zeng Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid Am J Physiol Gastrointest Liver Physiol 299 2010 G887 897
18. A. Alisi, L. Da Sacco, G. Bruscalupi, F. Piemonte, N. Panera, and R. De Vito Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease Lab Invest 91 2011 283 293
19. Y. Murakami, T. Yasuda, K. Saigo, T. Urashima, H. Toyoda, and T. Okanoue Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues Oncogene 25 2006 2537 2545
20. Y. Colak, O. Ozturk, E. Senates, I. Tuncer, E. Yorulmaz, and G. Adali SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease Med Sci Monit 17 2011 HY5-9
21. V. Audrito, T. Vaisitti, D. Rossi, D. Gottardi, G. D'Arena, and L. Laurenti Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network Cancer Res 71 2011 4473 4483
22. H. Chen, Y. Sun, R. Dong, S. Yang, C. Pan, and D. Xiang Mir-34a is upregulated during liver regeneration in rats and is associated with the suppression of hepatocyte proliferation PLoS One 6 2011 e20238
23. Z. Gao, J. Zhang, I. Kheterpal, N. Kennedy, R.J. Davis, and J. Ye Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity J Biol Chem 286 2011 22227 22234
24. R.E. Castro, J.D. Amaral, S. Sola, B.T. Kren, C.J. Steer, and C.M. Rodrigues Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes Am J Physiol Gastrointest Liver Physiol 293 2007 G327 334
25. X. Jin, Y.P. Chen, M. Kong, L. Zheng, Y.D. Yang, and Y.M. Li Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways J Gastroenterol Hepatol 2011
26. S. Cermelli, A. Ruggieri, J.A. Marrero, G.N. Ioannou, and L. Beretta Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease PLoS One 6 2011 e23937
27. N. Li, S. Muthusamy, R. Liang, H. Sarojini, and E. Wang Increased expression of miR-34a and miR-93 in rat liver during aging, and their impact on the expression of Mgst1 and Sirt1 Mech Ageing Dev 132 2011 75 85
28. H.K. Min, A. Kapoor, M. Fuchs, F. Mirshahi, H. Zhou, and J. Maher Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease Cell Metab 15 2012 665 674
29. C. Benz, S. Angermuller, G. Otto, P. Sauer, W. Stremmel, and A. Stiehl Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes Eur J Clin Invest 30 2000 203 209
30. H. Malhi, and G.J. Gores Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Semin Liver Dis 28 2008 360 369
31. +/- mice: a role of lipid mobilization and inflammation Endocrinology 151 2010 2504 2514
32. A. Purushotham, T.T. Schug, Q. Xu, S. Surapureddi, X. Guo, and X. Li Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation Cell Metab 9 2009 327 338
33. C.L. Brooks, and W. Gu The impact of acetylation and deacetylation on the p53 pathway Protein Cell 2 2011 456 462
34. J.D. Amaral, R.E. Castro, S. Sola, C.J. Steer, and C.M. Rodrigues Ursodeoxycholic acid modulates the ubiquitin-proteasome degradation pathway of p53 Biochem Biophys Res Commun 400 2010 649 654
35. K.D. Lindor, K.V. Kowdley, E.J. Heathcote, M.E. Harrison, R. Jorgensen, and P. Angulo Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 2004 770 778
36. V. Ratziu, V. de Ledinghen, F. Oberti, P. Mathurin, C. Wartelle-Bladou, and C. Renou A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis J Hepatol 54 2011 1011 1019
37. T. Tsuchida, M. Shiraishi, T. Ohta, K. Sakai, and S. Ishii Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-A(y) mice Metabolism 2011
38. V.U. Buko, I.A. Kuzmitskaya-Nikolaeva, E.E. Naruta, O.Y. Lukivskaya, S.N. Kirko, and H.D. Tauschel Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet Hepatol Res 41 2011 647 659